18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19759099.
- Also identified by DOI 10.2967/jnumed.108.055780 and PMC identifier 2899678.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. (18)F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of (18)F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of (18)F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.
Medical subject headings
- Fluorodeoxyglucose F18
- Positron-Emission Tomography
- Radiotherapy, Intensity-Modulated
- Tomography, X-Ray Computed